Paradox breakers — promising novel RAF inhibitors

被引：0
|
作者：
Diana Romero
机构：
来源：
Nature Reviews Clinical Oncology | 2016年 / 13卷 / 1期
关键词：
D O I：
10.1038/nrclinonc.2015.195
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：2 / 2
相关论文
共 50 条
  • [41] Synthesis of Substituted Aminopyrimidines as Novel Promising Tyrosine Kinase Inhibitors
    N. V. Stolpovskaya
    A. A. Kruzhilin
    A. V. Zorina
    Kh. S. Shikhaliev
    I. V. Ledeneva
    E. A. Kosheleva
    D. Yu. Vandyshev
    Russian Journal of Organic Chemistry, 2019, 55 : 1322 - 1328
  • [42] Paradox-Breaking RAF Inhibitors that Also Target SRC Are Effective in Drug-Resistant BRAF Mutant Melanoma
    Girotti, Maria Romina
    Lopes, Filipa
    Preece, Natasha
    Niculescu-Duvaz, Dan
    Zambon, Alfonso
    Davies, Lawrence
    Whittaker, Steven
    Saturno, Grazia
    Viros, Amaya
    Pedersen, Malin
    Suijkerbuijk, Bart M. J. M.
    Menard, Delphine
    McLeary, Robert
    Johnson, Louise
    Fish, Laura
    Ejiama, Sarah
    Sanchez-Laorden, Berta
    Hohloch, Juliane
    Carragher, Neil
    Macleod, Kenneth
    Ashton, Garry
    Marusiak, Anna A.
    Fusi, Alberto
    Brognard, John
    Frame, Margaret
    Lorigan, Paul
    Marais, Richard
    Springer, Caroline
    CANCER CELL, 2015, 27 (01) : 85 - 96
  • [43] The Raf Inhibitor Paradox: Unexpected Consequences of Targeted Drugs
    Cox, Adrienne D.
    Der, Channing J.
    CANCER CELL, 2010, 17 (03) : 221 - 223
  • [44] Paradoxical activation of Raf by a novel Raf inhibitor
    Hall-Jackson, CA
    Eyers, PA
    Cohen, P
    Goedert, M
    Boyle, FT
    Hewitt, N
    Plant, H
    Hedge, P
    CHEMISTRY & BIOLOGY, 1999, 6 (08): : 559 - 568
  • [45] Novel AGE-breakers
    Rahbar, S
    Figarola, JL
    Scott, S
    Gonzales, N
    DIABETES, 2002, 51 : A501 - A501
  • [46] Discovery of a novel class of potent Raf kinase inhibitors: Structure activity relationships.
    Lowinger, TB
    Riedl, B
    Wood, J
    Dumas, J
    Smith, RA
    Khire, U
    Bankston, D
    Monahan, MK
    Scott, WJ
    Lee, W
    Johnson, JS
    Caringal, Y
    Turner, T
    Gane, T
    Kennure, N
    Barbosa, J
    CLINICAL CANCER RESEARCH, 2000, 6 : 4533S - 4533S
  • [47] Molecular design of tyrosinase inhibitors: A critical review of promising novel inhibitors from synthetic origins
    Khan, Mahmud Tareq Hassan
    PURE AND APPLIED CHEMISTRY, 2007, 79 (12) : 2277 - 2295
  • [48] Clinical Status of RAF/MEK Inhibitors
    Weber, J.
    Daud, A.
    Infante, J.
    Sosman, J.
    Flaherty, K.
    Kefford, R.
    Hamid, O.
    Schuchter, L.
    Patel, K.
    Gonzalez, R.
    EUROPEAN JOURNAL OF CANCER, 2012, 48 : 10 - 10
  • [49] Adaptive resistance to RAF inhibitors in melanoma
    Kugel, Curtis H., III
    Aplin, Andrew E.
    PIGMENT CELL & MELANOMA RESEARCH, 2014, 27 (06) : 1032 - 1038
  • [50] RAS/RAF/MEK Inhibitors in Oncology
    Rusconi, P.
    Caiola, E.
    Broggini, M.
    CURRENT MEDICINAL CHEMISTRY, 2012, 19 (08) : 1164 - 1176
12345